Adalimumab in active ulcerative colitis: a "real-life" observational study.
Summary
Adalimumab shows effectiveness in ulcerative colitis patients refractory to other treatments. Early clinical remission predicts better long-term outcomes and reduces colectomy rates in this real-world study.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Effectiveness of adalimumab for ulcerative colitis (UC) remains debated.
- Controlled trials show modest absolute clinical benefit over placebo.
- This study evaluates adalimumab's real-world effectiveness in Italian UC patients.
Purpose of the Study:
- To assess the effectiveness of adalimumab in a cohort of ulcerative colitis patients.
- To identify predictors of long-term clinical remission.
- To evaluate secondary outcomes including steroid discontinuation and colectomy rates.
Main Methods:
- Retrospective review of 88 ulcerative colitis patients treated with adalimumab.
- Co-primary endpoints: clinical remission at 4, 12, 24, and 54 weeks.
- Secondary endpoints: sustained remission, steroid discontinuation, endoscopic remission, and colectomy.
Main Results:
- Clinical remission rates at 54 weeks were 43.2%.
- Early clinical remission and low C-reactive protein at week 12 predicted week 54 remission.
- Previous immunosuppressant use was linked to lower remission and higher colectomy rates.
Conclusions:
- Adalimumab demonstrates effectiveness in medically refractory ulcerative colitis patients in a real-world setting.
- Achieving early remission with adalimumab is associated with better long-term outcomes.
- Real-world data supports adalimumab's role in managing challenging ulcerative colitis cases.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...